Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial

Hyeong Dong Yuk, Chang Wook Jeong, Cheol Kwak, Hyeon Kim, Kyung Chul Moon, Ja Hyeon Ku, Hyeong Dong Yuk, Chang Wook Jeong, Cheol Kwak, Hyeon Kim, Kyung Chul Moon, Ja Hyeon Ku

Abstract

Introduction: Atezolizumab is a programmed death ligand-1 inhibitor for urothelial bladder cancer treatment. Atezolizumab has become the standard therapy for patients with urothelial bladder cancer who are not responding to cisplatin-based chemotherapy and is also used as a first-line treatment in cisplatin-ineligible patients. However, the efficacy of atezolizumab as a neoadjuvant chemotherapy for radical cystectomy has not yet been published and is still under study. This trial investigates the effectiveness of basal/squamous-like (BASQ) classification in the selection of an effective target group of patients with muscle-invasive bladder cancer (MIBC) for neoadjuvant atezolizumab treatment.

Methods and analysis: This study is an open-label, two-cohort, phase II trial. It was designed to evaluate the efficacy of neoadjuvant atezolizumab treatment in patients with MIBC (T2-4N0M0) pathological responses after neoadjuvant chemotherapy and radical cystectomy. According to the molecular subtype characteristics of previous transurethral resection of the bladder specimens, patients are divided into two groups: luminal type (KRT5/6-KRT14-FOXA1+GATA3+) and basal type (KRT5/6+KRT14+FOXA1-GATA3-). Every 3 weeks, atezolizumab is administered at a dose of 1200 mg for three cycles prior to radical cystectomy in patients with MIBC. The primary end point is objective pathological responses in the intention-to-treat patients. The secondary end point is a 1-year progression-free survival difference according to the BASQ classification in patients who underwent neoadjuvant atezolizumab treatment.

Ethics and dissemination: The study protocol was approved by the Institutional Review Board of Seoul National University Hospital, Seoul, Republic of Korea (H 1806-051-950). The trial is registered at ClinicalTrials.gov. The trial results will be published in peer-reviewed journals and at conferences.

Trial registration number: NCT03577132.

Keywords: genitourinary medicine; immunology; urological tumours.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flow diagram. PET, positron emission tomography; PLND, pelvic lymphadenectomy; TURB, transurethral resection of the bladder.

References

    1. Donin NM, Lenis AT, Holden S, et al. . Immunotherapy for the treatment of urothelial carcinoma. J Urol 2017;197:14–22. 10.1016/j.juro.2016.02.3005
    1. Kates M, Sopko NA, Matsui H, et al. . Immune checkpoint inhibitors: a new frontier in bladder cancer. World J Urol 2016;34:49–55. 10.1007/s00345-015-1709-y
    1. Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol 2018;59:285–96. 10.4111/icu.2018.59.5.285
    1. Suzman DL, Agrawal S, Ning Y-M, et al. . Fda approval summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist 2019;24:563–9. 10.1634/theoncologist.2018-0084
    1. Gupta S, Gill D, Poole A, et al. . Systemic immunotherapy for urothelial cancer: current trends and future directions. Cancers 2017;9. 10.3390/cancers9020015. [Epub ahead of print: 27 Jan 2017].
    1. Massari F, Santoni M, di Nunno V, Nunno di, et al. . Adjuvant and neoadjuvant approaches for urothelial cancer: updated indications and controversies. Cancer Treat Rev 2018;68:80–5. 10.1016/j.ctrv.2018.06.002
    1. Necchi A, Anichini A, Raggi D, et al. . Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol 2018;36:3353–60. 10.1200/JCO.18.01148
    1. Powles T, Kockx M, Rodriguez-Vida A, et al. . Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019;25:1706–14. 10.1038/s41591-019-0628-7
    1. Pichler R, Horninger W, Heidegger I. ASCO 2018: highlights of urothelial cancer and prostate cancer. Memo 2018;11:284–90. 10.1007/s12254-018-0422-0
    1. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315–22. 10.1038/nature12965
    1. Choi W, Porten S, Kim S, et al. . Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25:152–65. 10.1016/j.ccr.2014.01.009
    1. Hoadley KA, Yau C, Wolf DM, et al. . Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158:929–44. 10.1016/j.cell.2014.06.049
    1. Lindgren D, Frigyesi A, Gudjonsson S, et al. . Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463–72. 10.1158/0008-5472.CAN-09-4213
    1. Lerner SP, McConkey DJ, Hoadley KA, et al. . Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer 2016;2:37–47. 10.3233/BLC-150037
    1. Volkmer J-P, Sahoo D, Chin RK, et al. . Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A 2012;109:2078–83. 10.1073/pnas.1120605109
    1. Rosenberg JE, Hoffman-Censits J, Powles T, et al. . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20. 10.1016/S0140-6736(16)00561-4
    1. Sharma P, Retz M, Siefker-Radtke A, et al. . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312–22. 10.1016/S1470-2045(17)30065-7
    1. Perou CM, Sørlie T, Eisen MB, et al. . Molecular portraits of human breast tumours. Nature 2000;406:747–52. 10.1038/35021093

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner